96 results on '"Briscoe, K."'
Search Results
2. A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial
3. Evaluation of serum galactomannan detection for diagnosis of feline upper respiratory tract aspergillosis
4. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
5. 635P Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer
6. 596P Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
7. A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial
8. Systemic Bacillus Calmette-Guerin sepsis manifesting as hypercalcaemia and thrombocytopenia as a complication of intravesical Bacillus Calmette-Guerin therapy
9. 1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
10. 586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
11. Neutropenic fever rates with adjuvant docetaxel and cyclophosphamide in early breast cancer: audit from regional cancer centre in New South Wales
12. Microstructure and Microtribology of Polymer Surfaces
13. Coffs Carcinoid cluster: Is there something in the water?
14. Coffs Carcinoid cluster: All in the family?
15. Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration resistant prostate cancer
16. INFECTION CONTROL IN CORRECTIONAL HEALTHCARE
17. DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result
18. OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result
19. Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)
20. Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study
21. 1805TiP - Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)
22. A Phase 3 Randomised Trial of Adding Nitroglycerin to First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer: the Australasian Lung Cancer Trials Group Nitro Trial
23. Patients’ preferences for adjuvant chemotherapy (ACT) in early colon cancer (ECC): What makes it worthwhile?
24. 1245P - A Phase 3 Randomised Trial of Adding Nitroglycerin to First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer: the Australasian Lung Cancer Trials Group Nitro Trial
25. Enhanced acute myocardial infarction detection algorithm using local and global signal morphology.
26. Enhanced methods for the collection of on-scene information by emergency medical system providers.
27. Studying China: A Source Book for Teachers in Schools and Colleges C. Howe
28. Broadening horizons: Institutionalizing an international perspective.
29. Sustained complete remission of metastatic sweat gland carcinoma following regional hyperthermic perfusion
30. NEOPLASMS
31. Enhanced acute myocardial infarction detection algorithm using local and global signal morphology
32. Enhanced methods for the collection of on-scene information by emergency medical system providers
33. Colleges, like companies, need vision to...
34. Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
35. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
36. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
37. ECHO+: An Innovative Technology-Enabled Collaborative Learning and Quality Improvement Program Strengthening Rural Primary Care in Arkansas, West Virginia, and Oklahoma.
38. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
39. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
40. Discharge interventions for First Nations people with a chronic condition or injury: a systematic review.
41. Codesigning informative resources for families of Aboriginal and Torres Strait Islander children who sustained a burn injury: a protocol for a participatory action research study.
42. Which Way? Indigenous-led Smoking Cessation Care: Knowledge, Attitudes and Practices of Aboriginal and Torres Strait Islander Health Workers and Practitioners - A National Cross-sectional Survey.
43. "It Needs a Full-Time Dedicated Person to Do This Job in Our Local Communities with Our Aboriginal Health Services"-Aboriginal and Torres Strait Islander Health Workers and Practitioners Perspectives on Supporting Smoking Cessation during Pregnancy.
44. Discharge Interventions for First Nations People with Injury or Chronic Conditions: A Protocol for a Systematic Review.
45. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
46. Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer.
47. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
48. MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).
49. Immunotherapy-related gastritis: Two case reports and literature review.
50. The indirect impacts of COVID-19 on Aboriginal communities across New South Wales.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.